Chemokines and their receptors are involved in several allergic diseases. We measured RANTES and MCP-llevels in sera of allergic rhinitis patients, and we also evaluated the effect of cetirizine, a secondgeneration HI antagonist, on these chemoattractant proteins.
Baseline serum levels ofRANTES and MCP-l chemokines were significantly higher (p < 0.02 and p =0.007, respectively) in allergic patients than in the healthy control group. Cetirizine resulted in a significant decrease in RANTES (p < 0.02) and MCP-l (p =0.003) versus baseline values. There is an increase in RANTES and MCP-l in allergic rhinitis, which is counteracted by cetirizine.
Several biologically active substances are known to mediate allergic inflammation (1) (2) (3) (4) (5) . Recently, interest is increasingly being focused on the role of chemokines in the pathophysiology of allergic diseases and on their potential as targets of therapy (6) . Discovered over two decades ago (7, 8) , this burgeoning family of chemoattractant cytokines is involved in inflammatory reactions (9) (10) (11) . Chemokines and chemokine receptors form a sophisticated system that regulates leukocyte and lymphocyte traffic across various compartments: from the tissue of origin and from the blood to the sites of inflammation. Chemokines affect the synthesis of cellular proteins, the production of other chemokines, and the behaviour of stimulated cells (12) . There is low linkage specificity between chemokines and their membrane receptors: a receptor can bind different chemokines, and a chemokine can likewise bind different receptors.
The role of chemokines in many inflammatory diseases is well established, but little is known about chemokines in allergic rhinitis. Consequently, the aim of this study was to measure serum levels of RANTES and MCP-l, which are CC chemokines, in patients with allergic rhinitis. The study was devoted to evaluate also the effect of cetirizine, a second-generation HI antagonist, on the RANTES and MCP-l serum levels.
MATERIALS AND METHODS

Patients
Fifteen patients (10 males and 5 females) aged between 14 and 68 years (mean, 26.7 years) were enrolled in the study. Patients were suffering from perennial or seasonal allergic rhinitis. They all had a history of sneezing, nasal obstruction, rhinorrhea, and nasal itching. Skin prick test and RAST showed hypersensitivity to Dermatophagoides pteronyssinus (D.pt) in 8 patients and to grasses in the other 7 patients. Exclusion criteria were: 1) previous specific immunotherapy for D.pt or grasses; 2) use of drugs that could interfere with cetirizine (sodium cromoglycate, vasoconstrictors or other antihistamines) with a minimum washout of2 weeks for topical agents and 4 weeks for systemic agents; 3) use of other investigational drugs within 30 days before entry into the study; and 4) use of non topical corticosteroids within three months before the study. Patients with nasal polyps or other nasal deformities were excluded from the study. Pregnant and nursing women were not eligible for the study. Similarly, renal, hepatic, cardiovascular and other systemic diseases were considered contraindicated for the study. No patient had a history of bronchial asthma or was affected by this disease at the time of the study, even in a subclinical form (13, 14) . All patients evaluated by spirometry, had lung function parameters within predicted values.
Patients with allergy to D.pt were studied from October to January. Allergic subjects to grasses were examined during the pollen season. As controls, five healthy subjects (mean age 30.4 years, range 17-35 years,3 males and 2 females) were selected. No control had a personal or family history of atopy, and in vivo and in vitro diagnostic tests for allergic diseases were negative.
Study design
The selected patients gave their informed consent to the study. The study design required two weeks of treatment with 10 mg of cetirizine once a day, followed by two weeks of washout. To evaluate the effect of cetirizine on serum chemokines, 10 ml of peripheral venous blood were collected from each patient before and after the two weeks of cetirizine treatment and again after two weeks of washout. Samples were centrifuged at 1500 rpm for 10 min at room temperature. Serum aliquots were stored at -20°C until required for assay.
Chemokine assay
Serum levels of RANTES were measured with a quantitative sandwich enzyme immunoassay (Immunos, Albany, CA, USA). Briefly, a monoclonal antibody anti-RANTES was incubated with sera of patients in a 96-microwell plate at room temperature for 3 h. After incubation, a polyclonal antibody conjugated with alkaline phosphatase was added, and a colorimetric reaction was developed by adding the colour reagent solution. The reaction was blocked by a stop solution, and then measured by a spectrophotometer at 450 nm. The lowest detectable dose of RANTES was <5 pg/ml. Serum levels of MCP-l were measured with an enzyme immunoassay. The only difference, from RANTES detection was the method. Endogen human monocyte chemoattractant protein-l serum levels were measured with the ELISA MCP-l procedure (Endogen Inc, Woburn, MA, USA), and the monoclonal antibodies were against MCP-l. The lowest detectable dose of MCP-l was < 10 pg/ml.
Statistical analysis
All blood samples were collected at the same time of the day to avoid differences caused by the circadian changes. Tests were performed with kits from the same lot. Results were analysed by paired and unpaired t test. Probability (p) values = 0.05 were considered significant.
RESULTS
In allergic patients ( Fig. 1) , the baseline serum levels of RANTES (mean ± SD: 1195.3 ± 653.2 pg/ml) were significantly (p < 0.02) higher than in healthy controls (mean ± SD: 359 ± 160.4 pg/ml). After cetirizine treatment, serum RANTES levels decreased (mean ± SD: 797.7 ± 496.2pg/ ml) significantly (p < 0.02). After two weeks of washout, RANTES levels increased (mean ± SD: 943 ±520.6 pg/ml) and they were not significantly different from baseline values.
A similar trend was observed for MCP-l ( Fig.  2) . In allergic rhinitis, baseline MCP-l values (mean ± SD: 1357.3 ± 294.5 pg/ml) were significantly (p = 0.007) higher than in controls (mean ± SD: 924.0 ± 180.2 pg/ml). After cetirizine therapy, serum MCP-l levels (1080 ± 187.0 pg/ml) decreased significantly (p =0.003). Two weeks after antihistamine washout, MCP-I values increased (1160.7 ± 382.1 pg/ml) and they were not significantly different from baseline levels. RANTES values were slightly, but not significantly, increased ( Fig. 3) after cetirizine treatment in 2 cases of seasonal rhinitis (patients 7 and 9) and 1 case of perennial rhinitis (patient 14). Similarly, MCP-l levels were slightly, but not significantly increased in 2 with perennial rhinitis (again patients 7 and 9) and in 1 with seasonal rhinitis (patient 3) after treatment (Fig. 4) . However, the differences were slight, except in patient 9. 
DISCUSSION
Leukocytes are essential for the response to injury. Leukocytes are attracted to the site of inflammation by several substances. Chemokines are important mediators of the recruitment of leukocytes that are activated and they release substances able to amplify inflammation. The cellular pattern of the inflammatory infiltrate largely depends on the type of disease and whether it is acute or chronic. It also depends on the kind of chemokines that are expressed in the damaged tissue. Re sident tissue cells, leukocytes, and cytokine-activated endothelial cells secrete chemokines. In a wide spectrum of disorders chemokines levels are increased and able to sub-vert the phy siological distribution of leukocytes (12) .
The increased RANTES and MCP-I serum levels found in our patients demonstrate that chemokines playa key role also in allergic rhinitis as they do in other allergic disorders, and that a second-generation HI receptor antagonist can counteract enhanced chemokine levels.
After treatment and washout, RANTES and MCP-I concentrations showed the same trend in the two forms of rhinitis.
The reduction in RANTES and MCP-l concentrations obtained in our patients was undoubtedly due to the antihistamine therapy, which is supported by the following data too . After the treatment, the serum values of these two chemokines were not significantly different (RANTES: p > 0.08; MCP-I: p > 0.1) between allergic and healthy subjects (Fig. 1,2) . As well as, no significant difference was observed in allergic group between the basal serum level of RANTES (p > 0.2) and MCP-I (p > 0.1) and those detected after two weeks of washout, in relation with the exhausting of the pharmacological action of the treatment (Figs. 1,2) . The chemokine-reducing effect of the H I antagonist could be related to the HI-receptor block induced by cetirizine. This block would limit inflammation because less histamine binds to the specific receptor. Consequently, less chemoattractant proteins would be released, and there would be a lower recruitment and activation of cells that are potentially inflammatory and that release other chemokines.
An alternative explanation for the chemokinereducing effect of cetirizine concerns the low linkage specificity between chemokines and their receptors. Given their remarkable heterogeneity, chemokine receptors could bind cetirizine thus blocking resident cells. This would result in a decreased release of other chemokines that reduce the recruitment of circulating cells and consequently the chemokines release at the site of inflammation. Chemokines influence the synthesis of cellular proteins and the production of other chemokines as well as they influence the behaviour of the stimulated cells (12) . Fig. 3 . Rantes values detected before (0), after two weeks of cetirizine treatment (I), and again after two weeks of wash-out (8) . Considering that T cells respond to the CC chemokines including MCP-I, the antihistamine treatment could be hypothesized as indirectly influencing the T cells functions in allergic inflammation (6, 12, 15) .
Cetirizine could block the receptor sites of other chemoattractant mediators. By decreasing RANTES and MCP-I serum levels, cetirizine reduces allergic inflammation, which is in agreement with the experimental in vitro study showing that cetirizine inhibits RANTES release from IFN)'stimulated keratinocytes (16) .
Apart the direct or indirect effects exerted on chemokines, cetirizine could affect other less wellknown targets. For instance, cetirizine is known to attenuate eosinophil infiltration in skin in vivo, which suggests an anti-inflammatory mode of action distinct from its usual anti-HI activity (17) .
Lastly, cetirizine could also exert a specific effect on chemokines, given the evidence that second-generation HI antagonists seem to prevent the release in vivo of other mediators of inflammation besides histamine (18) (19) (20) .
In conclusion, in allergic rhinitis, after the early phase, characterized by mastcell activation, the ongoing process of inflammation in the nasal mucosa leads to the accumulation of secondary inflammatory cells recruited mainly by chemokines (23, 24) . The recruited cells are all involved in orchestrating the development of the late phase of allergic inflammation with the chronicization of disease, that could extend to involve lung. The high chemokines serum levels found in allergic rhinitis strengthen the opinion that, even if it is not a fatal condition, however allergic rhinitis is often trivialized and not rightly considered (14, 19) . Inflammation potentially is able to pass the limits of the nose involving lung structure (20) . In fact, allergic rhinitis is a high risk factor (15-40%) for bronchial asthma development , as reported by different authors (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) and in our previous paper (14, 31) .
Further studies are required to establish how cetirizine affects the release of mediators, other than histamine, from activated cells involved in allergic inflammation. Lastly, this study indicates that chemokines are a potential target for antiinflammatory strategies.
